Month: February 2022

Atossa Therapeutics Announces Year-End 2021 Financial Results and Provides Corporate Update

Written by Customer Service on February 28, 2022. Posted in Earnings Releases And Operating Results.

SEATTLE, Feb. 28, 2022 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter and fiscal year ended December 31, 2021 and provides an update on recent company developments. Key developments from Q4 2021 and to date include:Initiated enrollment of our Phase 2 clinical study of proprietary oral Z-endoxifen (or “Endoxifen”) in Sweden. Participants in the study will be premenopausal women with measurable mammographic breast density.Completed a pre-investigational new drug (PIND) meeting with the FDA. The purpose of the meeting was to obtain input from the FDA on pre-clinical, clinical, manufacturing...

Dominion Lending Centres Completes Newton Acquisition

Written by Customer Service on February 28, 2022. Posted in Mergers And Acquisitions.

VANCOUVER, British Columbia, Feb. 28, 2022 (GLOBE NEWSWIRE) — Dominion Lending Centres Inc. (TSX:DLCG) (“DLC” or the “Corporation”) is pleased to announce that it has completed the acquisition of the remaining 30% of 10017078 Canada Inc. (“Newton Holdco”) that DLC did not already own (the “Newton Acquisition”), which transaction was previously announced on February 15, 2022. Newton Holdco owns 100% of the issued and outstanding shares of Newton Connectivity Systems Inc. The Newton Acquisition was completed pursuant to a share purchase agreement dated February 15, 2022 between the Corporation and Next4 Holdings Inc. (“Next4”). The Corporation completed the Next4 Acquisition by paying Next4 an aggregate purchase price of $24,000,000, comprised of: (i) a cash payment of $16,865,000; and (ii) the issuance of 1,853,247 class “A” common...

Vaxcyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Written by Customer Service on February 28, 2022. Posted in Earnings Releases And Operating Results.

— First Participants Dosed in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults — — VAX-24 Phase 1/2 Study Topline Safety, Tolerability and Immunogenicity Results Expected by End of 2022 — — $273.1 Million in Cash, Cash Equivalents and Investments as of December 31, 2021, Excluding Net Proceeds of Approximately $107.6 Million from Recent Public Offering — — Company to Host Webcast/Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT — SAN CARLOS, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the fourth quarter...

AppFolio, Inc. Announces Fourth Quarter and Fiscal Year 2021 Financial Results

Written by Customer Service on February 28, 2022. Posted in Earnings Releases And Operating Results.

Revenue grows 32 percent year-over-year in the fourth quarter SANTA BARBARA, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) — AppFolio, Inc. (NASDAQ: APPF) (“AppFolio” or the “Company”), a leading provider of cloud business management solutions for the real estate industry, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2021. “I’m pleased to announce that in the fourth quarter we expanded our number of units served to 6.35 million and revenue from continuing operations grew 32%, capping off a year of 26% growth. This shows that we are driving success with our ongoing multi-year investments,” said Jason Randall, President and CEO, AppFolio. “In 2022, our talented team continues to focus on igniting revenue growth by continuing to make it increasingly easy for our customers...

Pennant Reports Fourth Quarter and Full Year 2021 Results

Written by Customer Service on February 28, 2022. Posted in Earnings Releases And Operating Results.

Conference Call and Webcast scheduled for tomorrow, March 1, 2022 at 10:00 am MT EAGLE, Idaho, Feb. 28, 2022 (GLOBE NEWSWIRE) — The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced its operating results for the fourth quarter and fiscal year 2021, reporting GAAP diluted earnings per share of $0.09 and $(0.08) for the full year ended December 31, 2021 and the fourth quarter, respectively. Pennant also reported adjusted diluted earnings per share of $0.46 for the year and $0.07 for the quarter(1). Full Year and Quarter HighlightsTotal revenue was $439.7 million for the fiscal year 2021, an increase of $48.7 million or 12.5% over the prior year, and total revenue for the quarter was $111.8 million, an increase of $3.8 million...

Surgery Partners, Inc. Announces Fourth Quarter and Full Year 2021 Results; Raises 2022 Guidance

Written by Customer Service on February 28, 2022. Posted in Earnings Releases And Operating Results.

Net loss attributable to common stockholders was $0.1 million for the fourth quarter 2021; $81.2 million for the full-year 2021Fourth quarter 2021 Adjusted EBITDA increased 26.0% over the prior year period to $114.4 million, inclusive of an $11.6 million benefit from the recognition of CARES Act grants Full-year 2021 Adjusted EBITDA increased 32.3% over the prior year period to $339.6 million, inclusive of a $25.3 million benefit from the recognition of CARES Act grantsRevenues increased 11.3% to $610.2 million in the fourth quarter 2021 and 19.6% to $2.2 billion in the full-year 2021, when compared to the comparable periods in 2020Days adjusted same-facility revenues increased 9.6% in the fourth quarter 2021 versus 2020, including case volume growth of 4.2% Days adjusted same-facility revenues increased 18.1% in the full-year...

MIMEDX Announces Fourth Quarter and Full Year 2021 Operating and Financial Results

Written by Customer Service on February 28, 2022. Posted in Earnings Releases And Operating Results.

Fourth Quarter Net Sales of $67.4 Million and Full Year 2021 Net Sales of $258.6 Million; Reflects a Double-Digit Revenue Increase in the Company’s Continuing Portfolio of Products Vibrant Commercial Business is Funding New Product Development Initiatives and Promising Late-stage Musculoskeletal Pipeline Management to Host Conference Call Today at 5:00 PM ET MARIETTA, Ga., Feb. 28, 2022 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced the filing of its 2021 Annual Report on Form 10-K for the year ended December 31, 2021. Timothy R. Wright, MIMEDX Chief Executive Officer, commented, “The above-market growth of 15% in our Advanced Wound Care products in 2021 is a direct result of the investments we have made to align our sales...

CTS Acquires Industry Leader in Temperature Sensors

Written by Customer Service on February 28, 2022. Posted in Mergers And Acquisitions.

LISLE, Ill., Feb. 28, 2022 (GLOBE NEWSWIRE) — CTS Corporation (NYSE: CTS) has completed the acquisition of TEWA Temperature Sensors SP. Zo.o. and its subsidiaries for an enterprise value of $24.5 million. TEWA is a reputable designer and manufacturer of high-quality temperature sensors. The company has a reputation for highly stable and reliable ceramic technology that has accelerated its growth. Based in Lublin, Poland, TEWA was founded in 1964 and serves customers across Europe and North America. The company is a strong complement to CTS’s temperature sensing platform and will expand CTS’s presence in Europe. “We are excited to add another talented team to the CTS family,” said Kieran O’Sullivan, CEO of CTS Corporation. “The acquisition of TEWA supports our end market diversification strategy. The combination of TEWA’s distribution...

Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress

Written by Customer Service on February 28, 2022. Posted in Earnings Releases And Operating Results.

RAS(ON) Inhibitor Pipeline Continues to Advance and Expand, Now Addressing Majority of RAS-Addicted Cancers; Two New Drug Candidates Recently Nominated Recently Announced First Patient Dosed in Global Phase 2 Study Evaluating Combination of RMC-4630 and Lumakras™ (sotorasib) in Patients with Advanced Non-Small Cell Lung Cancer mTORC1-Selective Inhibitor, RMC-5552, Demonstrates Preliminary Evidence of Clinical Activity in Ongoing Phase 1/1b Monotherapy Study REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced its financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update. “Revolution Medicines continues to advance our integrated...

Metromile Announces Fourth Quarter and Full Year 2021 Financial Results

Written by Customer Service on February 28, 2022. Posted in Earnings Releases And Operating Results.

SAN FRANCISCO, Feb. 28, 2022 (GLOBE NEWSWIRE) — Metromile, Inc. (“Metromile”) (NASDAQ: MILE, MILEW), a leading digital insurance platform and pay-per-mile auto insurer, today announced financial results for the fourth quarter and full year 2021 on its website. The results are accessible on Metromile’s investor relations website at ir.metromile.com. Due to the pending transaction with Lemonade announced on November 8, 2021, the Company will not host a conference call in conjunction with its fourth quarter and full year 2021 earnings release. Please visit the Investor Relations section of the Company’s website at http://ir.metromile.com for the latest releases and information. About Metromile Metromile (NASDAQ: MILE, MILEW) is a leading digital insurance platform in the United States. With data science as its foundation, Metromile...

Month: February 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice